C
Impaired glucose tolerance
18
evidence score
Also known as: glucose intolerance, glucose intolerance/diabetes mellitus, impaired glucose tolerance (2-hour postglucose load of 140-199 mg/dL)
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 9meta-analyses: 0trials: 9genetic: 0MR bonus:
References (7)
0 meta-analyses / systematic reviews- Adverse effects of glucocorticoids: coagulopathy. — European journal of endocrinology 2015 · PMID 25971647
- Evidence-based hypertension treatment in patients with diabetes. — Journal of clinical hypertension (Greenwich, Conn.) 2011 · PMID 22277142
- Diabetes, prediabetes and cardiovascular risk. — European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology 2010 · PMID 20489420
- Dysglycemia/prediabetes and cardiovascular risk factors. — Reviews in cardiovascular medicine 2009 · PMID 20065930
- Smoking-induced metabolic disorders: a review. — Diabetes & metabolism 2008 · PMID 18468932
- Insulin resistance and atherosclerosis. — The Journal of clinical investigation 2006 · PMID 16823479
- Obesity as a risk factor for cerebrovascular disease. — The Keio journal of medicine 2004 · PMID 15096722
Clinical trials (7)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT05500937 | Effect of UDCA on the New Onset Diabetes and Glucose Intolerance Induced by Statin-A Multicenter, Prospective, Random Controlled Trial | UNKNOWN | INTERVENTIONAL | UDCA |
| NCT01972542 | The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk in Healthy People, Impaired Glucose Tolerance and Type 2 Diabetes | COMPLETED | INTERVENTIONAL | Oral fat tolerance test |
| NCT01068860 | A Multi-center, Double-blind, Placebo-controlled, Randomized Study to Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes Treated With Differing Baseline Diabetes Therapies | COMPLETED | INTERVENTIONAL | Canakinumab 150 mg, Placebo to Canakinumab |
| NCT02355509 | Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients | COMPLETED | INTERVENTIONAL | Acarbose, Placebo |
| NCT00122447 | CVD Risk and Prevention in Early Glucose Intolerance | COMPLETED | INTERVENTIONAL | Aspirin, Alpha lipoic acid, Olmesartan |
| NCT00097786 | A Multinational, Randomized, Double-blind, Placebo-controlled, Forced-titration, 2 x 2 Factorial Design Study of the Efficacy and Safety of Long-term Administration of Nateglinide and Valsartan in the Prevention of Diabetes and Cardiovascular Outcomes in Subjects With Impaired Glucose Tolerance (IGT) | COMPLETED | INTERVENTIONAL | Valsartan 160 mg + nateglinide 60 mg, Valsartan 160 mg + nateglinide placebo, Nateglinide 60 mg + valsartan placebo |
| NCT04451616 | Assessment of Progranulin and Chemokine-like Protein TAFA-5 (FAM19A5) Blood Levels in Adults With Metabolic Syndrome | UNKNOWN | OBSERVATIONAL | Blood sample collection, Hair sample collection, Urine sample collection |
Genetic associations (0)
None linked.